利培酮治疗儿童少年精神分裂症的对照研究

A controlled study of risperedone in child schizophrenia

目的:探讨利培酮治疗儿童少年精神分裂症的疗效及安全性。方法:将40例符合中国精神障碍分类及诊断标准第三版诊断标准的儿童少年精神分裂症患者随机分成两组,分别给予利培酮与奋乃静治疗8周,用简明精神病评定量表(BPRS)和副反应量表(TESS)评定疗效和不良反应。结果:两组之间疗效差异无显著性,但利培酮组不良反应较奋乃静组少。结论:利培酮治疗儿童少年精神分裂安全有效,不良反应少。

Objective：To explore the curative effects and safety of risperedone in child schizophrenia. Methods：40 child schizophrenia who met the diagnostic critenia of CCMD -3 were randomly divided into risperedone group or perphenazine group, They were tredted by risperedone or perphenazine for 8 weeks, Brief Psychiatric Rating Scale（BPRS） and Treatment Emergent Symptom scale （TESS） were used to evaluate the efficaly and side effects respectively. Results： There was no significant difference in efficaly between these two groups, but side effects of risperdone were less than those of perphenazine. Conclusions： Risperedone is safe and effective in the treatment of child schizophrenia.